Changes of lipoprotein(a) levels with endogenous steroid hormones
- PMID: 34695230
- PMCID: PMC9286445
- DOI: 10.1111/eci.13699
Changes of lipoprotein(a) levels with endogenous steroid hormones
Abstract
Background: Lipoprotein(a) [Lp(a)] is an LDL-like molecule that is likely causal for cardiovascular events and Lp(a) variability has been shown to be mostly of genetic origin. Exogenous hormones (hormone replacement therapy) seem to influence Lp(a) levels, but the impact of endogenous hormone levels on Lp(a) is still unknown. The aim of the study was to assess the effect of endogenous steroid hormone metabolites on Lp(a).
Methods: Lipoprotein(a) levels were measured in 1,021 participants from the Swiss Kidney Project on Genes in Hypertension, a family-based, multicentre, population-based prospective cohort study. Endogenous levels of 28 steroid hormone precursors were measured in 24-h urine collections from 883 individuals. Of the participants with Lp(a) data, 1,011 participants had also genotypes available.
Results: The participants had an average age of 51 years and 53% were female. Median Lp(a) levels were 62 mg/L, and the 90th percentile was 616 mg/L. The prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. Forty-three per cent of Lp(a) variability was explained respectively by: age (2%, p < .001), LDL-C (1%, p = .001), and two SNPs (39%, p value<2⋅10-16 ). Of the 28 endogenous steroid hormones assessed, androstenetriol, androsterone, 16α-OH-DHEA and estriol were nominatively associated with serum Lp(a) levels in univariable analyses and explained 0.4%-1% of Lp(a) variability, but none of them reached significance in multivariable models.
Conclusions: In this contemporary population-based study, the prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. The effect of endogenous steroid hormone levels of Lp(a) variability was small at best, suggesting a negligible impact on the wide range of Lp(a) variability.
Keywords: cardiovascular risk; endogenous hormones; lipoprotein (a).
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Conflict of interest statement
FM is national PI of a clinical study by Novartis on Lp(a) lowering, GE is investigator of the same study and has received research grants, consulting, and speaking fees (minor) from Amgen, Boehringer, Daiichi‐Sankyo, MSD, Novartis, Recordati, Sanofi, Servier. MP has received consultancy and speaking fees from Novo Nordisk and Astellas.
Figures

Similar articles
-
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).J Am Heart Assoc. 2016 Apr 23;5(4):e003012. doi: 10.1161/JAHA.115.003012. J Am Heart Assoc. 2016. PMID: 27108248 Free PMC article.
-
Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional study in healthy males.Horm Metab Res. 1994 Dec;26(12):602-8. doi: 10.1055/s-2007-1001768. Horm Metab Res. 1994. PMID: 7705766 Clinical Trial.
-
Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy.Clin Nutr. 1999 Oct;18(5):319-22. doi: 10.1016/s0261-5614(98)80031-9. Clin Nutr. 1999. PMID: 10601541
-
Lipoprotein(a), cardiovascular disease, and contemporary management.Mayo Clin Proc. 2013 Nov;88(11):1294-311. doi: 10.1016/j.mayocp.2013.09.003. Mayo Clin Proc. 2013. PMID: 24182706 Review.
-
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.Curr Atheroscler Rep. 2019 Jul 27;21(10):37. doi: 10.1007/s11883-019-0803-9. Curr Atheroscler Rep. 2019. PMID: 31350625 Review.
References
-
- Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998;82(12A):57U‐66U. discussion 86U. - PubMed
-
- Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis. 2002;163(2):377‐384. - PubMed
-
- Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1‐22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous